Spaulding Clinical, a leading clinical research organization (CRO), is expanding its services to include ADME (absorption, distribution, metabolism, and excretion) clinical trials
Spaulding Clinical, a leading clinical research organization
(CRO), is expanding its services to include ADME (absorption, distribution,
metabolism, and excretion) clinical trials. This strategic addition further
solidifies Spaulding Clinical’s commitment to delivering comprehensive
solutions to pharmaceutical and biotechnology companies worldwide.
ADME studies are vital components
of drug development, providing critical insights into the behavior of drugs
within the human body. By measuring the absorption, distribution, metabolism,
and excretion of a drug, these trials offer valuable data on its safety,
efficacy, and pharmacokinetics.
“With the addition of ADME studies
to our suite of services plus hired staff with over 60 years combined
experience in conducting these trial types, Spaulding Clinical is positioned to
better support our clients in making informed decisions during drug
development,” said Cassandra Erato, CEO of Spaulding
Clinical. “These trials play a pivotal role in understanding the behavior and
fate of a drug in the body, allowing researchers to optimize dosage, assess
potential drug-drug interactions, and enhance overall drug safety profiles.”
Spaulding Clinical’s
state-of-the-art facilities, equipped with cutting-edge technology and staffed
by highly trained professionals, provide an ideal environment for conducting
ADME studies. The company’s extensive experience in conducting Phase I trials,
combined with its commitment to scientific excellence and regulatory
compliance, ensures the delivery of high-quality data to support the
development and regulatory approval of new drugs.
Erato added: “Our clients rely on
us for the fastest results in Phase I. Adding these services allows us to
deliver the full package of Phase I studies in record time to help
groundbreaking new therapies get to proof of concept faster.”
About Spaulding Clinical
Research
Founded in 2007, Spaulding Clinical is a full-service, state-of-the-art
paperless Phase I clinical pharmacology unit. Our facility, originally a
hospital, features fully integrated bedside electronic data capture and sets
the standard for patient care. We specialize in IND-enabling clinical
pharmacology studies, cardiovascular safety, and clinical proof of concept. We
provide expertise on study design, offering in-house medical writing, clinical
data management, biostatistics, project management, clinical laboratory, and
PK/PD analysis. For high-quality data to inform your decisions, Think Spaulding
First. To learn more, visit spauldingclinical.com.